国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2010年
10期
1919-1921
,共3页
LASEK%MMC%haze
LASEK%MMC%haze
LASEK%MMC%haze
目的:不同浓度丝裂霉素(MMC)对LASEK术后效果的影响方法:选择261例496眼LASEK患者随机分为两组,0.4mg/mL MMC(mytomycin C ,MMC)组133例245眼,0.2mg/mL MMC组128例251眼,于LASEK手术完毕后滴于切削区,根据屈光度＜-3.00,-3.25～-6.00,-6.25～-9.00,＞-9.25分别置留30,60,90,110s,术后随访两组患者视力、haze、角膜内皮细胞密度及眼压和术后用药时间.结果:随访1a,术后1a haze的发生率,0.4mg/mL MMC组1.2%,0.2mg/mL MMC组13.2%;术后1a时,0.4mg/mL MMC组影响视力者为0.8%,0.2mg/mL MMC组2.0%.术后1,6,12mo患者等值球镜变化情况,0.4mg/mL MMC组分别为:-0.52±0.09,-0.29±0.15,-0.35±0.16;0.2mg/mL MMC组分别为:-0.67±0.11D,-0.58±0.21D,-0.54±0.18D.术前及术后1,6,12mo角膜内皮镜检查角膜内皮细胞密度情况,0.4mg/mL MMC组分别为:2994.01±321.89,2974.89±339.87,3001.02±306.92,3011.18±321.31;0.2mg/mL MMC组分别为:3005.92±382.54,2996.69±374.19,2988.37±367.33,3000.05±299.84.两组各指标的比较,差异有统计学意义(P<0.05).0.4mg/mL MMC组取镜后出现2例3眼丝状角膜炎;0.2mg/mL MMC组取镜后出现2例2眼丝状角膜炎.结论:术中使用0.4mg/mL MMC可以减少LASEK术后并发症,使用较为方便,并且安全有效,效果优于0.2mg/mLMMC.
目的:不同濃度絲裂黴素(MMC)對LASEK術後效果的影響方法:選擇261例496眼LASEK患者隨機分為兩組,0.4mg/mL MMC(mytomycin C ,MMC)組133例245眼,0.2mg/mL MMC組128例251眼,于LASEK手術完畢後滴于切削區,根據屈光度＜-3.00,-3.25～-6.00,-6.25～-9.00,＞-9.25分彆置留30,60,90,110s,術後隨訪兩組患者視力、haze、角膜內皮細胞密度及眼壓和術後用藥時間.結果:隨訪1a,術後1a haze的髮生率,0.4mg/mL MMC組1.2%,0.2mg/mL MMC組13.2%;術後1a時,0.4mg/mL MMC組影響視力者為0.8%,0.2mg/mL MMC組2.0%.術後1,6,12mo患者等值毬鏡變化情況,0.4mg/mL MMC組分彆為:-0.52±0.09,-0.29±0.15,-0.35±0.16;0.2mg/mL MMC組分彆為:-0.67±0.11D,-0.58±0.21D,-0.54±0.18D.術前及術後1,6,12mo角膜內皮鏡檢查角膜內皮細胞密度情況,0.4mg/mL MMC組分彆為:2994.01±321.89,2974.89±339.87,3001.02±306.92,3011.18±321.31;0.2mg/mL MMC組分彆為:3005.92±382.54,2996.69±374.19,2988.37±367.33,3000.05±299.84.兩組各指標的比較,差異有統計學意義(P<0.05).0.4mg/mL MMC組取鏡後齣現2例3眼絲狀角膜炎;0.2mg/mL MMC組取鏡後齣現2例2眼絲狀角膜炎.結論:術中使用0.4mg/mL MMC可以減少LASEK術後併髮癥,使用較為方便,併且安全有效,效果優于0.2mg/mLMMC.
목적:불동농도사렬매소(MMC)대LASEK술후효과적영향방법:선택261례496안LASEK환자수궤분위량조,0.4mg/mL MMC(mytomycin C ,MMC)조133례245안,0.2mg/mL MMC조128례251안,우LASEK수술완필후적우절삭구,근거굴광도＜-3.00,-3.25～-6.00,-6.25～-9.00,＞-9.25분별치류30,60,90,110s,술후수방량조환자시력、haze、각막내피세포밀도급안압화술후용약시간.결과:수방1a,술후1a haze적발생솔,0.4mg/mL MMC조1.2%,0.2mg/mL MMC조13.2%;술후1a시,0.4mg/mL MMC조영향시력자위0.8%,0.2mg/mL MMC조2.0%.술후1,6,12mo환자등치구경변화정황,0.4mg/mL MMC조분별위:-0.52±0.09,-0.29±0.15,-0.35±0.16;0.2mg/mL MMC조분별위:-0.67±0.11D,-0.58±0.21D,-0.54±0.18D.술전급술후1,6,12mo각막내피경검사각막내피세포밀도정황,0.4mg/mL MMC조분별위:2994.01±321.89,2974.89±339.87,3001.02±306.92,3011.18±321.31;0.2mg/mL MMC조분별위:3005.92±382.54,2996.69±374.19,2988.37±367.33,3000.05±299.84.량조각지표적비교,차이유통계학의의(P<0.05).0.4mg/mL MMC조취경후출현2례3안사상각막염;0.2mg/mL MMC조취경후출현2례2안사상각막염.결론:술중사용0.4mg/mL MMC가이감소LASEK술후병발증,사용교위방편,병차안전유효,효과우우0.2mg/mLMMC.
